The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT06325826
- Lead Sponsor
- Egyptian Liver Hospital
- Brief Summary
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Adult patients aged 18 years or older.
- Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4)
- achieved SVR for HCV after DAAs.
Exclusion Criteria
- Previous interferon (IFN) treatment.
- Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection.
- Current hepatocellular carcinoma (HCC) or other malignancies.
- Previous history of HCC or HCC intervention.
- Liver cell failure, liver transplantation or renal impairment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatocellular Carcinoma 24 month Number of Participants develop New Hepatocellular Carcinoma
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Egyptian Liver Hospital
🇪🇬Talkha, Dakahlia, Egypt
Egyptian Liver Hospital🇪🇬Talkha, Dakahlia, Egypt